

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box with 1 blister of 2 tablets
Box with 2 blisters of 2 tablets

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VetUK cat Wormer 16 mg/40 mg film-coated tablets

≥ 2 kg

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:

Milbemycin oxime 16 mg

Praziquantel 40 mg

3. PACKAGE SIZE

2 tablets

4 tablets

4. TARGET SPECIES

Cats (weighing at least 2 kg).

5. INDICATIONS

For products not subject to veterinary prescription:

In cats: treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms) of the following species:

Cestodes:

Echinococcus multilocularis,

Dipylidium caninum,

Taenia spp.,

Nematodes:



Ancylostoma tubaeforme,

Toxocara cati

Prevention of heartworm disease (*Dirofilaria immitis*), if concomitant treatment against cestodes is indicated.

6. ROUTES OF ADMINISTRATION

Oral use

	 Tablet
2 – 4 kg	x1/2
>4 – 8 kg	x1
>8 – 12 kg	x1½

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

This veterinary medicinal product does not require any special temperature storage conditions.

Half tablets should be stored in the original blister and be used for the next administration.

Keep the blister in the outer carton.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

ALFAMED

14. MARKETING AUTHORISATION NUMBERS

Vm 17902/3012

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Blister of 2 tablets

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VetUK cat Wormer



≥ 2 kg

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

16 mg/ 40 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

VetUK cat Wormer 16 mg/40 mg film-coated tablets for cats

2. Composition

Each tablet contains:

Active substances:

	Appearance	Milbemycin oxime	Praziquantel
Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 4 mg/10 mg film-coated tablets for small cats and kittens	Oval shaped, dark brown, meat flavoured tablets with a score on both sides.	4 mg	10 mg
Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 16 mg/40 mg film-coated tablets for cats	Oval shaped, red to pink, meat flavoured tablets with a score on both sides.	16 mg	40 mg

Excipients:

Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 4 mg/10 mg film-coated tablets for small cats and kittens	Iron oxide (E172)	0,3 mg
Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 16 mg/40 mg film-coated tablets for cats	Allura red AC (E129)	0,1 mg
	Titanium Dioxide (E171)	0,5 mg

The tablets can be divided into halves.

3. Target species

Cats.

4. Indications for use

In cats: treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms) of the following species:

Cestodes:

Echinococcus multilocularis,
Dipylidium caninum,
Taenia spp.,

Nematodes:

Ancylostoma tubaeforme,
Toxocara cati

Prevention of heartworm disease (*Dirofilaria immitis*), if concomitant treatment against cestodes is indicated.

5. Contraindications

Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 4 mg/10 mg film-coated tablets for small cats and kittens	Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 16 mg/40 mg film-coated tablets for cats
Do not use in kittens of less than 6 weeks of age and/or weighing less than 0.5 kg.	Do not use in cats weighing less than 2 kg

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

See also section "Special warnings".

6. Special warnings

Special warnings:

It is recommended to treat all the animals living in the same household concomitantly.

In order to develop an effective worm control programme local epidemiological information and the living conditions of the cat should be taken into account and therefore it is recommended to seek professional advice.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

When *Dipylidium caninum* infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.

Special precautions for safe use in the target species:

No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The veterinary medicinal product is not recommended for such animals or only according to the benefit-risk assessment by the responsible veterinarian.

Studies have shown that treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the veterinary medicinal product. In the absence of data on cats with microfilaraemia, its use should be according to a benefit risk assessment by the attending veterinarian.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of the reach of the animals.

As per good veterinary practice, animals should be weighed to ensure accurate dosing.

Ensure cats and kittens weighing between 0.5 kg and ≤ 2 kg receive the appropriate tablet strength (4 mg MBO/10 mg praziquantel) and the appropriate dose (1/2 or 1 tablet) for the corresponding weight band (1/2 tablet for cats weighing 0.5 to 1 kg ; 1 tablet for cats weighing >1 to 2 kg – 1 tablet).

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Do not handle this veterinary medicinal product in case of hypersensitivity to the active substances or to any of the excipients.

Wash hands after use.

Part tablets should be returned to the open blister pack and stored in the carton.

In case of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.

Other precautions:

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Pregnancy and lactation:

In a study, this combination of active substances was demonstrated to be well tolerated in breeding queens, including during pregnancy and lactation. As a specific study with this veterinary medicinal product has not been performed, use during

pregnancy and lactation only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

The concurrent use of the combination praziquantel/milbemycin oxime with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the veterinary medicinal product and other macrocyclic lactones. Also no such studies have been performed with reproducing animals.

Overdose:

In a study conducted with the veterinary medicinal product administered at 1X, 3X and 5X the therapeutic dose, and for a duration which exceeded the therapeutic indication, i.e. 3 times at 15 day-intervals, signs uncommonly reported at the recommended dose (see section “Adverse events”) have been observed at 5-fold the therapeutic dose after the second and third treatments. These signs disappeared spontaneously within a day.

7. Adverse events

Cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):
--

Hypersensitivity reaction ¹ Systemic disorders ¹ (e.g. Lethargy) Neurological disorders ¹ (e.g. Ataxia, Muscle tremor) Digestive tract disorders ¹ (e.g. Emesis, Diarrhoea)
--

¹ Especially in young cats.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally as a single dose.

The veterinary medicinal product should be administered with or after some food.

The veterinary medicinal product is a small size tablet.

To aid with administration, the veterinary medicinal product has been coated with a meat flavour.

Depending on the bodyweight of the cat, the practical dosing is as follows:

Weight	Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 4 mg/10 mg film-coated tablets for small cats and kittens	Milprotect (BE, NL) / VetUK cat Wormer (UK/NI) / Milprazikan (FR) 16 mg/40 mg film-coated tablets for cats
0.5 - 1 kg	1/2 tablet	
> 1 – 2 kg	1 tablet	
2 – 4 kg		1/2 tablet
>4 – 8 kg		1 tablet
>8 – 12 kg		1 + 1/2 tablets

The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The veterinary medicinal product has a duration of heartworm prevention of one month. For prevention of heartworm disease the use of a monosubstance is preferred.

9. Advice on correct administration

Not applicable.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Half tablets should be stored in the original blister and be used for the next administration.

Keep the blister in the outer carton.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the blister after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging (for half tablets): 6 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as milbemycin oxime may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 17902/3012

Available pack sizes:

- 1 box of 2 tablets containing 1 blister of 2 tablets
- 1 box of 4 tablets containing 2 blisters of 2 tablets

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

ALFAMED
13^{ème} rue LID
06517 Carros
France

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Gavin Hall

Approved: 10 September 2025